Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jy6t3j92

THERAPEUTICAL EVALUATION OF BIOACTIVE COMPOUNDS OF NIGELLA SATIVA FOR HER2-POSITIVE BREAST CANCER TREATMENT

Asif Bilal[1], Fouzia Tanvir[1*], Sibtain Ahmad[2,3*], Abdur Rehman Azam[4], Muhammad Qasim[5], Hasnain Zafar[6]

[1*]Department of Zoology, University of Okara, Okara Pakistan
[2*]Institute of Animal and Dairy Sciences, Faculty of Animal Husbandry, University of Agriculture, Faisalabad, Pakistan
[3]Center for Advanced Studies Agriculture and Food Security (CAS-AFS), University of Agriculture, Faisalabad, Pakistan
[4]Department of Pathobiology, College of veterinary medicine, University of Illinois at Urbana Champaign, USA
[5]Department of Zoology, University of Lahore Sargodha Campus, Sargodha Pakistan
[6]Institute of Zoology, Bahauddin Zakariya university, Multan, Pakistan

***Corresponding Authors:** Fouzia Tanvir, Sibtain Ahmad
*Emails: fouzia.tanvir@uo.edu.pk, dr_sibtainhmd6@uaf.edu.pk

Abstract: This study aims to discover the mechanisms by which phytoactive compounds from *Nigella sativa* exert anti-breast cancer effects through *in-silico* analysis, exploring their potential as promising therapeutic candidates against HER2-positive breast cancer treatment in particular. For this purpose, human epidermal growth factor receptor 2 was chosen based on their high protein-protein interaction scores. The protein sequence was retrieved from databases such as NCBI and UniProt. Structural modeling was performed using the SWISS-MODEL platform, Structural validation identified by the SAVES server and TM-align. Ligand preparations involved selecting ligands including 4-terpineol, Nigellidine, Carvacrol, Thymol, and Thymoquinone from the ChEBI database and filtering for specific criteria. Protein-ligand docking analysis was carried out using the PyRx program. ADME analysis performed by SwissADME. The target protein is a protease involved in the regulation of fetal growth and HER2+ breast cancer. Several compounds, such as 4-terpineol, Nigellidine, Carvacrol, Thymol, and Thymoquinone exhibit promising binding potential towards the target protein, with an affinity of -9.8 kcal/mol and rmsd scores of 21.079 and 18.688 angstroms, respectively. The results of this study provide a solid starting point for the development and offer potential therapeutic applications across therapeutics. It provides novel insights into candidates' properties as potential HER2 inhibitors, highlighting molecules like Nigellidine for further preclinical development against aggressive HER2-positive breast cancer treatment driven by this pathway pending more research.

Keywords: *Nigella sativa*, Phytochemicals, Molecular docking, HER2+BC, Treatment

INTRODUCTION

HER2-positive breast cancer is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein, which fuels the rapid growth and spread of cancer cells. This subtype of breast cancer poses unique challenges and necessitates targeted treatment strategies to effectively thwart its

progression and improve patient outcomes (Ahuja et al., 2024).

In the landscape of HER2-positive breast cancer treatment, a multifaceted approach is employed to tackle this formidable adversary. One of the cornerstones of therapy involves the use of targeted therapies specifically designed to inhibit the HER2 protein and impede its oncogenic signaling pathways. Drugs such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) have revolutionized the treatment of HER2-positive breast cancer, offering patients more personalized and effective options to combat this aggressive disease (Dent et al., 2007).

Beyond targeted therapies, the management of HER2-positive breast cancer often involves a comprehensive treatment plan that may include surgery, chemotherapy, radiation therapy, and hormone therapy, tailored to the individual needs of each patient. The advent of neoadjuvant and adjuvant therapies has further enhanced treatment outcomes by shrinking tumors before surgery and reducing the risk of recurrence postoperatively. As research continues to unravel the complexities of HER2-positive breast cancer, novel therapeutic approaches, including immunotherapies and precision medicine, hold promise for further improving the prognosis and quality of life for patients battling this challenging disease (Bilal et al., 2021).

HER2-positive breast cancer treatment is a dynamic and evolving field, driven by the relentless pursuit of innovative therapies and personalized medicine. By harnessing the power of targeted treatments, multidisciplinary care, and cutting-edge research, we stand at the forefront of a new era in the fight against HER2-positive breast cancer, where hope shines brightly for improved outcomes and a brighter future for patients facing this formidable foe (Li et al., 2017).

The treating HER2-positive breast cancer with the potent arsenal of phytochemicals, herbs, and bioactive compounds. In the quest for innovative and holistic approaches to combat this aggressive form of cancer, the spotlight turns to the realm of natural compounds derived from plants and herbs, known for their potential therapeutic benefits in cancer management. The unique properties of phytochemicals and bioactive compounds hold promise in targeting HER2-positive breast cancer cells, offering a complementary avenue to traditional treatment modalities (Lehmann et al., 2011).

The intricate interplay between phytochemicals, herbs, and bioactive compounds and their impact on HER2-positive breast cancer treatment is a subject of burgeoning interest and research. These natural compounds possess diverse mechanisms of action that may impede the proliferation of HER2-positive cancer cells, inhibit tumor growth, and induce apoptosis, offering a multifaceted approach to combating this aggressive subtype of breast cancer. The exploration of these botanical treasures as adjunct therapies in conjunction with conventional treatments opens new avenues for enhancing the efficacy and tolerability of HER2-positive breast cancer management (Foulkes et al., 2010).

As we navigate the landscape of HER2-positive breast cancer treatment with phytochemicals, herbs, and bioactive compounds, a harmonious fusion of ancient wisdom and modern science emerges. The rich tapestry of botanical remedies and natural compounds presents a promising frontier in the quest for personalized and integrative approaches to cancer care. By harnessing the power of nature's pharmacy, we embark on a journey of discovery and innovation, seeking to unlock the therapeutic potential of these natural treasures in the fight against HER2-positive breast cancer. Together, let us explore the synergies between traditional wisdom and scientific advancement to pave the way for a brighter future in the treatment of HER2-positive breast cancer with phytochemicals, herbs, and bioactive compounds (Huo et al., 2012).

It has been connected to an increased frequency of mutations in the BRCA1 gene, which is essential for DNA repair processes. Furthermore, those who have a family history of ovarian and breast cancer are more likely to be affected. It frequently manifests as a more aggressive type of breast cancer, with a greater propensity for distant metastases, a larger tumor size, and a higher prevalence of lymph node involvement. Targeted therapies including hormonal therapy and HER2-targeted drugs are unsuccessful in treating it because of the lack of hormone receptors and HER2 overexpression (Sajjad et al., 2024).

HER2-positive is a heterogeneous disease with diverse molecular subtypes. Gene expression profiling has identified several molecular subtypes, including basal-like 1 and 2, mesenchymal-like, and luminal androgen receptor. These subtypes exhibit distinct gene expression patterns and are associated with different clinical outcomes and treatmentresponses (vonMinckwitz et al., 2012).

Chemotherapy remains the primary treatment modality, due to the lack of targeted therapies. Standard

chemotherapy regimens, such as anthracyclines and taxanes, are commonly used in the neoadjuvant and adjuvant settings. However, the response rates to chemotherapy vary among patients, highlighting the need for personalized treatment approaches (Noor et al., 2024).

In the realm of phytochemicals, herbs, and bioactive compounds, a diverse array of botanical treasures awaits exploration for their potential therapeutic benefits in HER2-positive breast cancer treatment. From the vibrant hues of turmeric to the soothing essence of green tea, each natural ingredient harbors unique bioactive properties that may hold the key to inhibiting HER2 signaling pathways, reducing inflammation, and promoting cellular health (Robson et al., 2017). The synergy between these botanical allies and traditional cancer therapies offers a promising avenue for enhancing treatment outcomes and mitigating the side effects associated with conventional approaches. Immune checkpoint inhibitors, including pembrolizumab and atezolizumab, have demonstrated efficacy in the patients with high levels of tumor-infiltrating lymphocytes (Schmid et al., 2020).

As we navigate the intricate web of phytochemical interactions within the context of HER2-positive breast cancer, the concept of personalized medicine takes center stage (Afzal et al., 2024). However, recent research has shed light on the damaging effects of the protein mutation in certain pathological conditions. The individualized response to phytochemicals, herbs, and bioactive compounds underscores the importance of tailoring treatment strategies to the unique biological profiles and needs of each patient (Conover, 2015).

Studies have identified elevated levels of HER2 in the synovial fluid and cartilage of Osteoarthritis patients Through a holistic approach that integrates botanical remedies with conventional therapies, we embark on a journey of discovery, adaptation, and optimization, seeking to optimize the efficacy and safety of HER2-positive breast cancer treatment (Sowers et al., 2004). Furthermore, the exploration of phytochemicals, herbs, and bioactive compounds in the context of HER2-positive breast cancer treatment heralds a new era of research and innovation (Kessler et al., 20216). It is not only involved in pregnancy-related processes but has also gained attention for its potential involvement in cancer development, including breast cancer. Breast cancer is the most commonly diagnosed cancer among women worldwide (Ferlay et al., 2018).

The elucidation of the molecular mechanisms underlying the anticancer properties of these natural compounds unveils a treasure trove of therapeutic potential waiting to be unlocked. By bridging the gap between traditional knowledge and modern science, we pave the way for a harmonious integration of nature's healing gifts into the fabric of cancer care, offering hope, resilience, and renewed possibilities for patients navigating the challenging terrain of HER2-positive breast cancer (Moverare-Skrtic et al., 2017). Protein expression was found to be significantly higher in breast cancer tissues compared to adjacent normal tissues (Marques et al., 2016).

Through the power of *in-silico* modeling and virtual screening, researchers can sift through vast libraries of herbal compounds to identify potential candidates that exhibit promising interactions with HER2 receptors. By leveraging computational algorithms and molecular docking simulations, scientists can predict how these bioactive molecules from herbs may bind to the HER2 protein, potentially inhibiting its overactive signaling and halting cancer cell proliferation (Kong et al., 2019). By harnessing the computational prowess of virtual screening techniques, researchers can expedite the drug discovery process, optimize therapeutic efficacy, and minimize potential side effects, paving the way for innovative treatment strategies in the fight against HER2-positive cancer (Moverare-Skrtic et al., 2017; Kong et al., 2019).

HER2 has emerged as a potential player in the unique landscape of the breast cancer. Its upregulation in tissues suggests its involvement in tumor development and progression. Protein’s interaction may contribute to the aggressive behavior observed in this type.

Aims and Objectives

To elucidate the molecular mechanisms underlying the anti-breast cancer activity of phytoactive compounds of *Nigella sativa* by in-silico analysis that may have a beneficial effect as a promising candidate for cancer therapy based on its critical role intreating HER2-positive breast cancer treatment.

MATERIALS AND METHODS

Selection of Proteins

The protein human epidermal growth factor receptor 2 (HER2) was selected for the experiment by Protein-protein interaction and docking analysis. The selected proteins have the highest docking score and interaction score.

Retrieval of Protein

The sequence of protein was collected from several databases, particularly NCBI (http://www.ncbi.nlm.nih.gov), and UniProt (https://www.uniprot.org) in Fasta format. This protein ID was Q9UK79.

Protein Modeling

The SWISS-MODEL platform (http://swissmodel.expasy.org) was used to create 3D configurations of both wild-type and mutant proteins in order to predict structural stability and changes. After employing homology modeling approaches to recover the native structure, a single-point mutation was then implemented in the pymol (https://pymol.org/2). A variety of wild and mutant models of both proteins were examined for energy using Chiron (https://dokhlab.med.psu.edu/chiron/login.php). At the end, the individual enhanced protein models are displayed, and each model can be downloaded as a PDB file.

Structural validation and RMSD calculation

The structural model was selected and subjected to a structural validation procedure using the SAVES server (https://saves.mbi.ucla.edu). SAVES incorporates PROCHECK and ERRAT to verify the 3D model's overall quality. Another technique for evaluating the model's quality was the RAMACHANDRAN plot that ProCHECK generated. The agreement between the primary and tertiary structures of a protein is evaluated by the three-dimensional validation. Next, TM-align (https://zhanglab.ccmb.med.umich.edu/TM-align) was used to compare the structures of wild-type and mutant proteins. This approach uses a superposition to calculate the template modeling score (TM-score) and the root mean square deviation (RMSD). The TM-score provides a number value between 0 and 1, which indicates a perfect match between the two structures. Greater structural divergence between wild-type and mutant forms is indicated by a higher RMSD value. In order to identify the preferred region of amino acids, the RAMAHANDRAN Plot additionally took into account the dihedral angle of atomsin amino acid residues.

Ligand Preparations

ChEBI database (http://www.ebi.ac.uk/chebi/), which includes commercially accessible chemicals for virtual screening, was used to select bioactive compounds such as 4-terpineol, Nigellidine, Carvacrol, Thymol, and Thymoquinone. We narrowed down our search from this vast library of billions of molecules to compounds that met specific criteria that improved the possibility of binding to our target receptors. In particular, we looked for compounds that fell within a specific molecular weight range and had functional groups that are known to take part in common protein-ligand binding interactions such charged motifs, hydrogen bonds, and aromatic interactions.

Protein-Ligand docking analysis

To identify ligand-protein interactions and possible ligands, molecular docking was used. To do this, we used the PyRx program (https://pyrx.sourceforge.io) to dock all of the chosen ligands with the protein. For virtual ligand screening, the Lamarckian genetic algorithm (LGA), which includes AutoDock and AutoDock Vina, was used. Each ligand's ten maximum exclusive values were determined by setting the active parameters to the largest center grid size. The default settings were applied to the remaining parameters. The binding affinities were computed and the PDB files were converted to PDBQT format using the AutoDock tools. The PubChem (https://pubchem.ncbi.nlm.nih.gov/) database provided the ligands' chemical structures. Discovery Studio (https://discover.3ds.com/discovery-studio-visualizerdownload) version 3 was utilized for virtual screening, allowing for the 2D and 3D interaction of ligands with proteins. They showed the size

and location of bonding sites, hydrogen bond interactions, hydrophobic interactions, and bonding distances of a docked ligand.

ADME Analysis Test

The initial screening of ligands was conducted using a web-based program, named SwissADME. The molecular weight, lipophilicity, Log P value, hydrogen bond donors, and hydrogen acceptors are the five factors were examined by this test. Ligands violation denotes that the drug is unfit for production, which is carried out by Lipinski's regulation.

Pharmacokinetics

The drug probability of various cannabinoids with binding energies lower than the control is analyzed using the SwissADME program, and six features are then taken into account to build a bioavailability radar. We consider the following six factors: size, polarity, saturation, lipophilicity, solubility, and flexibility. Any divergence from the pink-shaded area, which represents the ideal values of the six parameters, suggests that the ligand should not be orally accessible. Brain access and gastric adsorption are two crucial pharmacokinetic behaviors at different phases of the drug development process. the Brain Or IntestinaL EstimateDpermeation method (BOILED-Egg) is an accurate predictive model that computes the lipophilicity and polarity of tiny compounds. Predictions of both gut and brain penetration are derived from physical-chemical descriptors and subsequently translated into accurate, fast-running, and conceptually simple molecular designs by means of models. There are numerous uses for boiled eggs. It is helpful for drug development's early-stage library filtering through the final assessment. It is acquired using the SwissADME instrument.

RESULTS

Protein-Modeling

Based on steric constraints, the plot visualizes the preferred and permitted regions for residues to adopt by mapping the dihedral angles phi and psi of each peptide bond. The majority of points falling inside preferred regions show that the structure as a whole is physically sound and free of improper geometries. As expected for protein backbones, the great majority of HER2 residues are located comfortably in the upper left and lower right quadrants, which are core-favored regions. High stereospecificity without unlikely conformations brought on by modeling errors is suggested by the fact that only a small portion occupy less populated permitted areas.

Furthermore, no observations outside of favored/allowed zones fall inside the outlier region, which frequently represents erroneous structural elements. This offers compelling evidence that the computational homology model has accurately represented the fold of HER2 without any evident problems that might jeopardize the outcomes of simulations or docking studies carried out with this structure.

Thus, the Ramachandran analysis confirms that the model follows typical patterns found in known x-ray crystal structures, giving assurance that it can accurately depict the native protein topology and conformation for interaction or dynamic studies at the atomic level of detail. Before the model is used, its quality will be further characterized through ongoing evaluation using supplementary validation tools. Given the proper torsional distributions seen, the plot validates acceptable stereochemistry within the protein's computational structure, supporting its potential use as a representative receptor for future virtual screening or mechanistic analyses of this drug target (Figure 1).



Figure 1: Protein Modeling Analysis of HER2

Molecular docking analysis

The results of this computational exploration present a tapestry of binding affinities and structural insights that shed light on the potential therapeutic impact of 4-terpineol, Nigellidine, Carvacrol, Thymol, and Thymoquinone in targeting HER2-positive breast cancer.

In the realm of molecular docking, the binding affinity values serve as a compass guiding us towards understanding the strength of interaction between the bioactive compounds and the HER2 protein. The negative values of binding affinity signify favorable binding, indicating a potential for these compounds to form stable complexes with the HER2 receptor, thereby disrupting its oncogenic signaling pathways. Among the compounds, Nigellidine emerges as a potent binder with a strikingly high binding affinity of -9.8, suggesting a robust potential for therapeutic intervention in HER2-positive breast cancer.

Delving deeper into the realm of structural insights, the root-mean-square deviation (rmsd) values provide a lens through which we can assess the structural compatibility and stability of the HER2-bioactive compound complexes. The rmsd values in the upper bound and lower bound domains offer a glimpse into the conformational changes and variations in the binding poses of the compounds within the HER2 binding site. Noteworthy observations include the minimal rmsd values exhibited by 4-terpineol, Carvacrol, Thymol, and Thymoquinone in their interactions with the HER2 protein, indicating a high degree of structural complementarity and stability in their binding configurations.

Furthermore, the comparative analysis of the bioactive compounds reveals intriguing nuances in their

binding modes and affinity profiles with the HER2 receptor. Nigellidine, with its exceptional binding affinity and minimal rmsd values, emerges as a promising candidate for further exploration in targeted therapy for HER2-positive breast cancer. Conversely, compounds such as Thymoquinone exhibit slightly lower binding affinities and moderate rmsd values, suggesting a potential for optimization or structural refinement to enhance their efficacy as HER2 inhibitors.

The results of molecular docking of bioactive compounds from black cumin with the HER2 protein offer a compelling narrative of potential therapeutic avenues in the realm of HER2-positive breast cancer treatment. The intricate interplay of binding affinities, structural insights, and comparative analyses provides a roadmap for future research endeavors, paving the way for the development of novel targeted therapies that harness the power of natural compounds in combating this aggressive form of cancer. As we unravel the mysteries of molecular interactions and drug design, we embark on a journey of discovery and innovation, where the synergy between computational modeling and medicinal plants holds boundless promise for transforming the landscape of cancer care.

The molecular docking study provides insight into how well 4-terpineol may bind to and interact with HER2. The compound shows a binding affinity of -6.3 kcal/mol, indicating a moderately favorable therapeutic interaction. The root-mean-square deviation (RMSD) scores help evaluate how closely the docked ligand poses match the initial input structure. The RMSD values of 49.787 Å for the upper bound and 46.361 Å for the lower bound, while somewhat high, can be acceptable ranges depending on the size of the ligand. RMSD under 5 Å is generally preferred for tighter binding ligands. With tweaks focusing on the its pharmacophore, lead optimization seems promising for obtaining clinical candidates. Inhibiting protein's protease activity could prove clinically useful (Figure 2).

Carvacrol may interact with HER2 at the molecular level. Based on the findings, it demonstrates good binding potential towards HER2, with a computed binding affinity of -6.2 kcal/mol. It indicates the ligand and protein are predicted to form a stable complex driven by favorable non-covalent binding forces. The root-mean-square deviation scores of 70.573Å and 68.287Å for the upper and lower bounds, respectively, give a sense of how closely the ligand's docked conformation resembles its initial input structure. Continued molecular modeling will help elucidate important structure-activity relationships to guide medicinal chemistry efforts. These results establish a promising starting point meriting deeper evaluation of thymol as a lead compound for inhibiting the HER2 target (Figure 2).

The binding of Nigellidine achieves a respectable binding affinity of -9.8 kcal/mol for the protein target. This free energy of binding implies the ligand-protein complex would form spontaneously and have stability driven by non-covalent attractive forces between them. The RMSD scores of 26.988Å and 24.102Å for the upper and lower bounds respectively give an idea of how closely the docked poses mimic the natural conformation of this compound. A thoughtful iterative process of molecular modeling, synthesis and testing could support medicinal chemistry advancements toward novel HER2 inhibitors. If successful, such allosteric modulators may prove useful for conditions where regulating this protease activity could provide benefits. The docking predicts merits more rigorous evaluation and holds potential as a relevant chemical scaffold for developing selective pharmaceuticals targeting HER2 (Figure 2).

Thymol binding properties that are encouraging for further pursuing it as a lead compound. Thymol achieves a binding affinity of -6.3 kcal/mol for HER2, implying a stable, favored complex will form between ligand and protein driven by attractive intermolecular forces. The rmsd values of 21.079Å and 18.688Å for the upper and lower bounds respectively indicate its docked poses are reasonably close matches to its original conformation when binding. This docking study offers thymol as a potential scaffold deserving of more rigorous appraisal. Refining it as outlined could support developing selective HER2 pharmaceuticals with applications in problematic clinical contexts (Figure 2).

Thymoquinone demonstrates quite favorable binding potential towards HER2, with an estimated affinity of -6.1 kcal/mol. This strongly exothermic free energy of binding implies a very stable, favorably driven association between ligand and protein upon complex formation. The root-mean-square deviation scores of 6.077Å and 3.348Å for the upper and lower bounds respectively indicate thymoquinone's docked poses closely mimic its natural conformation when binding suitably within the active site. These low rmsd values are certainly encouraging for attaining desirable selectivity and potency. Considering the very strong affinity measured coupled with optimal rmsd readings achieved, the data lends promising initial evidence that it

warrants extensive additional investigation. It provides an apt molecular scaffold well deserving of intensive furtherevaluation towards developing customized HER2 biopharmaceuticals (Figure 2).



Figure 2: 2D protein-ligand interaction

Upon analyzing the molecular docking results, it is evident that various compounds, such as 4-terpineol, Nigellidine, Carvacrol, Thymol, and Thymoquinone exhibit promising binding potential towards the target protein. These compounds demonstrate favorable binding affinities, ranging from -6.1 kcal/mol to -9.8 kcal/mol, indicating stable and favorable interactions. Although some compounds have higher root-mean-square deviation (RMSD) scores, falling within an acceptable range, they still display the ability to adopt fitting poses within the active site of the protein. This suggests that further investigation and optimization of these compounds, such as through modifications and extensions, could enhance their potency and selectivity. The findings of this study provide a solid starting point for the development, inhibitors and offer potential therapeutic applications in conditions involving dysregulated protease activity. Here is all 3D structure of these bioactive compounds respectively.



Figure 3: 3D structure of protein-ligand interaction

In the provided table, each row represents a different compound, referred to as ligands, while the columns display crucial information about their binding affinity and root mean square deviation (rmsd) values. The binding affinity indicates the strength of the interaction between the ligand and the HER2, while the rmsd values provide insights into the structural alignment between the ligand and the target protein.

The table provided shows the results of molecular docking simulations performed between compounds HER2_4-terpineol, HER2_Carvacrol, HER2_Nigellidine, HER2_Thymol and HER2_Thymoquinone with the HER2 receptor protein.

In the docking studies, HER2_Nigellidine showed the strongest binding affinity of -9.8 kcal/mol among the compounds tested. This suggests it interacts most favorably with the active binding site of HER2 at the atomic level. HER2_4-terpineol, HER2_Carvacrol, HER2_Thymol and HER2_Thymoquinone also exhibited reasonably high binding affinities between -6.1 to -6.3 kcal/mol.

The next columns provide information on root mean square deviations (RMSDs) of poses obtained during docking. RMSD/ub measures deviation from the original crystallographic or best-known binding pose of the ligand, while RMSD/lb measures deviation from the docked pose obtained. In general, lower RMSD values indicate better reproduction of reference binding modes during docking simulations.

Across the compounds, HER2_Nigellidine also showed the lowest RMSD/ub and RMSD/lb values, pointing to its docked pose most closely resembling the actual binding conformation. The RMSD results thus corroborate well with its superior binding affinity observed. This *in-silico* analysis therefore suggests HER2_Nigellidine may have the highest binding effectiveness and makes it a promising lead for further optimization as an HER2-targeting therapeutic.

It is important to note that further analysis and experimental validation are necessary to confirm the functional significance of these interactions. Molecular docking results provide valuable initial insights, but additional studies are required to fully understand the biological implications and potential therapeutic applications of these compound-HER2 interactions.

The provided docking results offer a glimpse into the potential interactions between various compounds and the target protein. These findings lay the foundation for further investigations, which could potentially uncover novel avenues fortherapeutic interventions targeting protein (Table 1).

Table 1: Molecular docking analysis of protein and ligands

Ligands	Binding Affinity	Rmsd/ub	Rmsd/ib
4-terpineol	**-6.3**	**6.59**	**3.39**
Carvacrol	**-6.2**	**6.77**	**4.34**
Nigellidine	**-9.8**	**4.22**	**2.95**
Thymol	**-6.3**	**6.05**	**5.45**
Thymoquinone	**-6.1**	**4.78**	**2.84**

Pharmacokinetics

The pharmacokinetic profiles impact their drug development potential. Several compounds like Carvacrol and Nigellide demonstrated good predicted GI absorption classified as high, which suggests favorable oral bioavailability. Meanwhile, other molecules like Thymol displayed low predicted GI absorption, raising questions on oral dosing feasibility.

Most molecules except 4-terpineol exhibited no predicted blood-brain barrier penetration abilities as assessed by their BBB permeant classifications of no. This property could prevent unintended CNS side effects but limits applications for central diseases. Regarding membrane transporters, only Nigellidine were predicted P-gp substrates, a finding that may require consideration of drug-drug interactions.

None of the molecules were predicted strong inhibitors of the major CYP450 drug metabolizing isozymes according to the data provided, reducing drug-drug interaction liabilities from pharmacokinetic perspectives during combined therapies. Skin permeation rates varied widely as seen from the reported Log Kp values, a factor that determines transdermal drug delivery prospects.

Overall, while certain molecules (as 4-terpineol, Nigellidine, Carvacrol, Thymol, and Thymoquinone) present pharmacokinetic profiles supportive of oral drugs, every compound ca use necessitate non-oral formulations or structural modifications to achieve satisfactory in-vivo disposition. Further pharmacokinetic studies are warranted to fully realize the clinical translatability of these compounds.

The absorption properties of these molecules provide valuable insight into their potential for oral delivery. All the compounds show high predicted GI absorption, suggesting good oral bioavailability. However, factors like solubility and efflux transporters still require examination. On the other hand, thymol display low predicted GI absorption, making oral dosing challenging. This could necessitate non-oral formulations or structural modifications to improve gastrointestinal uptake. For example, pro-drug approaches may enhance solubility and permeability for these molecules.

The blood-brain barrier penetration abilities are also notable. Most molecules are not predicted to cross the BBB, which is favorable to avoid central nervous system side effects. However, this property limits therapeutic use for CNS diseases. Interestingly, as 4-terpineol and Nigellidine show potential BBB permeability according to the data. Further research is warranted to validate this *in-vitro*, and understand the mechanisms involved such as passive diffusion versus carrier-mediated transport. These molecules could have applications in treating neurological disorders if BBB transport is substantive.

Regarding transporters, many are predicted substrates for P-glycoprotein (P-gp). This efflux pump is expressed on intestinal and blood-brain barrier cells, and can cause drug-drug interactions by altering substrate absorption and brain entry. Close monitoring would be needed with known P-gp inhibitors or inducers. The other molecules do not appear to be significantly impacted by P-gp based on these computational models.

The data also provide preliminary insight into the metabolism of these compounds. As no strong CYP inhibition is predicted, off-target drug-drug interaction liabilities from pharmacokinetic mechanisms seem reduced. Nevertheless, experimental validation of metabolic pathways is still required before definitively assessing drug interaction risks. Overall, this *in-silico* pharmacokinetic analysis generates valuable leads but also highlights ongoing questions to address in further preclinical profiling of these interesting molecules (Figure 4).

Compounds	RADAR	Formula
4-terpineol		
Nigellidine		
Carvacrol		
Thymol		
Thymoquinone		

Figure 4: Pharmacokinetics RADARs of the all compounds

4-terpineol shows favorable predicted absorption parameters, with high GI absorption suggesting good oral bioavailability potential. While LogP values vary between computational models, most predict it as moderately lipophilic which may assist membrane permeation. It is also predicted to be a substrate for the efflux transporter P-gp, an important consideration for drug-drug interactions during combined therapies.

Nigellidine has no predicted BBB permeation, which could preclude CNS-focused applications depending on the target. However, its measured solubility and GI absorption classification of very soluble/high support oral drug development. It is predicted to have low GI absorption, indicating challenges for oral delivery, but high solubility may assist formulation strategies.

Moving to Carvacrol, key properties include high GI absorption, solubility and fulfilling many drug-likeness filters, supportive of an orally-available drug. It is also rated as having good predicted solubility and transport, but shows no calculated BBB penetration. It exhibits BBB penetrant potential *in-silico*, of interest for neurological targets pending experimental confirmation.

Thymol display more mixed profiles., these are predicted to have low GI absorption, complicating oral dosing without adaptations. Thymoquinone satisfies several drug properties but has multiple violated filters requiring monitoring. All lack substantial predicted BBB penetrance. Solubility also varies considerably between the computational methods for these entities. BOILED-egg shows the points of by number of arrows respectively. All the compounds of cumin have outstanding pharmaceutical properties (Figure 5).



Figure 5: Pharmacokinetics BOILED-egg of all compounds

The molecules demonstrate diverse predicted absorption and distribution behaviors *in-silico*. This highlights both opportunities and challenges for further development depending on the selectivity, potency and target indication of each individual bioactive compound. Combined with refinement of analytical techniques, this *in-silico* data can help optimization of candidate properties during early preclinical assessment.

DISCUSSION AND CONCLUSION

As described in the Results section, the vast majority of HER2 residues fall within the preferred phi/psi angle regions, demonstrating that the overall backbone conformation is physically sound and devoid of improper geometries. This suggests the modeling approach successfully captured the core packing motifs typical of globular protein structures. Additionally, the finding that no outliers exist outside allowed zones indicates the absence of unlikely conformations that could compromise downstream molecular docking or dynamics simulations performed with this model. This serves as strong evidence that the fold has been faithfully reproduced without notable errors.

When considering previously published X-ray crystallographic data on HER2 domains, the Ramachandran plot characteristics of the current model align well. Core-favored residues and lack of outliers have consistently been observed features of high-resolution HER2 crystal structures deposited in the Protein Data Bank.

As such, the torsional distributions seen here corroborate with patterns in the established literature for this receptor. This lends high confidence that the native protein conformation and topology have been accurately portrayed at the atomic level of detail required for mechanistic interaction and activity studies.

In summary, the Ramachandran plot validation suggests the computational homology approach was successful in generating a high-quality structural model of HER2 that faithfully conserves stereochemical features reported for the empirical protein structure. This supports the potential utility of the model for future virtual screening campaigns and investigations of HER2's function.

A recent report by Chen et al. inspected the limiting of different cocoa polyphenols to HER2. They found intensifies like epicatechin showed restricting affinities around - 7.5 kcal/mol, which is like ligands in the ongoing review going from - 5.1 to - 8.7 kcal/mol. While in the current study the certain ligands like Pappalysin-1_phenol and Pappalysin-1_naphthoquinones had less ideal at this point still sufficient rmsd ranges, their limiting affinities were additionally serious areas of strength formoderately - 5.1 and -

7.2 kcal/mol individually. In general, the uplifting partiality and arrangement measurements seen for various mixtures gives proof to potential HER2 connection and warrants further examination. Advancing augmentations from their center platforms utilizing PC supported drug configuration might assist with further developing strength. Propelling top medication like hits through displaying, blend and testing vows to yield promising HER2n inhibitory lead.

Also, rmsd values for epicatechin of 4-6 Å lined up with ideal scores seen here. This gives approval that the fondness levels and underlying fitting saw in the current outcomes are comparable to other revealed regular item cooperations with HER2. No solid CYP hindrance impacts were anticipated, diminishing askew metabolic medication association takes a chance with forthcoming exploratory affirmation. Variable anticipated skin pervasion and dissolvability relied upon the model used. While extra pharmacokinetic profiling is as yet required, these computational outcomes give prioritization direction and feature issues to address through proceeded with refinement and preclinical examinations to acknowledge clinical interpretation of thesebioactive mixtures.

Essentially, Zhang et al. in 2021 docked a few flavonoids and estimated affinities as solid as - 8.1 kcal/mol for baicalin, equivalent to top ligands in this review. Their most reduced rmsd of 2.9 Å for baicalin likewise coordinates intimately withideal scores here. This loans more trustworthiness that the docking convention used precisely models regular item restricting to HER2n at a level repeated by free examinations.

In any case, a key contrast was other work examining different framework types didn't reveal leads showing both liking and rmsd quality fair and square of Pappalysin-1_aloinoside_A, _phytosterol or _terpenoids distinguished here. Further assessment of construction action connections can offer knowledge on critical synthetic highlights for inhibitory action. Extra examination into organic system of restraint could lay out clinical practicality of focusing on HER2 for conditions including dysregulatedprotease movement.

This proposes these specific molecular structures could offer upgraded potential for improvement into high-performing HER2n inhibitors comparative with classes inspected somewhere else to date. Numerous ligands exhibited ideal restricting affinities to HER2n in the - 7 to - 8 kcal/mol range. Especially amazing were Pappalysin-1_aloinoside_A at - 8.6 kcal/mol, Pappalysin-1_phytosterol at - 8.7 kcal/mol, and Pappalysin-1_terpenoids at - 8.0 kcal/mol. These profoundly exothermic restricting energies demonstrate steady, useful buildings might shape between these ligands and HER2 determined by appealing intermolecular powers. A few ligands likewise accomplished positive primary arrangements inside the dynamic site as shown by low root-mean-square deviation values among docked and crystallographic compliances. Particularly encouraging were Pappalysin-1_aloinoside_A, Pappalysin-1_phytosterol and Pappalysin-1_anthraquinones, adjusting intimately with rmsd scores under 7 angstroms. This looks good for strong, particular associations.

A recent report by Huang et al. (2019) investigated the limiting of 20 conventional Chinese medication mixtures to HER2. A few normal items showed affinities around - 7.5 kcal/mol, like numerous ligands in the ongoing work. Compound 19 particularly showed an ideal proclivity of - 8.2 kcal/mol, matching the most grounded collaborations seen here.

They additionally noticed beneficial RMSD values between 2-4 Å for top hits like compound 19, resembling ideal arrangementsin the current outcomes. Be that as it may, their work didn't reveal leads displaying the mix of both high liking and underlying fitting fair and square of aloiniside A, phytosterol or terpenoids distinguished here.

In the meantime, Jiang et al. (2018) screened a characteristic flavonoid library and noticed promising restricting for specific mixtures. Baicalin showed a liking of - 7.9 kcal/mol which adjusts intimately with cumin's compounds in the ongoing review, and platyconi- C at - 8.0 kcal/mol matched terpenoids. Their rmsd scores under 4 Å likewise substantiate positive primary arrangements seen. While assessing different compound classes, the limiting boundaries from these different examinations supplement and build up the mooring convention and collaborations saw in the current exploration, while it uncovered some especially brilliant new inhibitor frameworks justifying sped up pursuit. By and large, while using assorted compound classes, the momentum restricting profiles certify well with discoveries from isolated research groups, approving this review's convention and results, while likewise revealing a few especially encouraging new molecular classes.

This study produced significant *in-silico* pharmacokinetic experiences into key mixtures. Comparative

information was accounted for by Chen et al. (2022) analyzing bioflavonoids. They found baicalin showed high anticipated GI ingestion and solvency inclining toward oral use, steady with discoveries for cumin's compounds here. Furthermore, Liu et al. (2021) profiling lignans additionally noticed great anticipated properties for certain analogs as seen for select particles in the ongoing work.

Nonetheless, a key distinction is neither one of the investigations revealed competitors like anthraquinones proposing potential BBB penetration. This remarkable perception of cumin's compounds and naphthoquinones merits consideration given ramifications for CNS focusing on forthcoming approval. The ongoing examinations likewise anticipated P-gp substrate potential for various mixtures, while earlier examinations didn't routinely test for carrier communications.

In the meantime, Garcia et al. (2018) and Zhang et al. (2019) describing terpenoids and curcuminoids found most needed BBB entrance *in-silico*. However, the previous distinguished goodrilin J displaying entrance, actually separating from this study's outcomes. The two works additionally revealed changing gastrointestinal retention forecasts among analogs, comparable to blended profiles seen by and by.

Ultimately, Jia et al. (2018) screening sesquiterpenes noted poor anticipated solvency/porousness requiring definition adaptions for some. These resembled difficulties expected for specific atoms thus founded on their solvency characterizations. Be that as it may, their top hits didn't show the double great dissolvability penetrability balance seen for favored up-and-comers in this review.

In rundown, while corresponding discoveries exist, this study uncovered new experiences from the perspective of various molecular pharmacophores yielding both supportive and particular results contrasted with past computational examinations (Bilal et al., 2022&2024). It further features competitor subsets justifying upgraded drug improvement thought and clinical examination.

This study gives significant experiences through molecular docking and *in-silico* pharmacokinetic profiling of different mixtures as likely leads towards creating HER2 inhibitor. The compounds showed promising anticipated ingestion qualities including high gastrointestinal take-up and solvency strong of oral bioavailability objectives for anticancer treatments. Generally, proceeded with investigation of the most encouraging up-and-comers holds vow to yield preclinical contender for repressing the pathogenic HER2 pathway ensnared in forceful breast cancer, a sign needing novel treatment draws near. Notwithstanding, thorough *in-vitro* and in-vivo pharmacokinetic and pharmacological examinations stay fundamental for laying out whether any could reasonably progress into clinical oncology preliminaries against this difficult illness space.

Authors' contributions

AB: wrote the manuscript, collected data and interpreted the results. FT: conceptualization and supervision. SA: supervision and study design. A R A : helped in writing. MQ and HZ: overviewed and formatted. All authors approved the version to be published and agreed to be accountable for all aspects of the work.

Acknowledgments

This research is a part the first author's (Asif Bilal) PhD thesis.

Funding

None

Data availability

The data used to support the findings of this research are available from the corresponding author upon request.

Conflict of interest

The authors declare that we have no conflict of interest.

REFERENCES

1. Bayes-Genis, A., Conover, C. A., Overgaard, M. T., Bailey, K. R., Christiansen, M., & Holmes Jr, D. R.

(2017). Pregnancy- associated plasma protein A as a marker of acute coronary syndromes. New England Journal of Medicine, 357(6), 664- 672.

2. Afzal, M., Ali, U., Riaz, A., Tanvir, F., Bilal, A., & Ahmad, S. (2024). In-silico analysis of deleterious single nucleotide polymorphisms (SNPs) of leukemia inhibitory factor (LIF), and their conformational predictions. Journal of Population Therapeutics and Clinical Pharmacology, 31(1), 2792-2811.
3. Chen, F. (2022). Computational evaluation of bioavailability and blood–brain barrier permeability of bioflavonoids. Scientific Reports, 12(1), 1-10. https://doi.org/10.1038/s41598-022-06256-4
4. Chen, Y., Han, C., Zheng, X., Liu, F., & Li, Y. (2020). Molecular docking and molecular dynamics simulation studies onthe interactions between cocoa polyphenols and pregnancy-associated plasma protein-A. Food & Function, 11(10),8867–8878. https://doi.org/10.1039/d0fo01449g
5. Conover, C. A. (2015). Key questions and answers about pregnancy-associated plasma protein-A. Trends in Endocrinology & Metabolism, 26(5), 242-249.
6. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., ... & Eisen, A. (2007). HER2-positive breast cancer treatment: clinical features and patterns of recurrence. Clinical Cancer Research, 13(15), 4429-4434.
7. Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., ... & Bray, F. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved from https://gco.iarc.fr/today
8. Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). HER2-positive breast cancer treatment. New England Journal of Medicine,363(20), 1938-1948.
9. Huang, Z., Li, W., Jin, Y., Qin, Y., & Jia, J. (2019). Computational screening of traditional Chinese medicine database for PAPP-A inhibitory constituents. Pharmaceutical Biology, 58(1), 589–595. https://doi.org/10.1080/13880209.2020.1727209
10. Sajjad, M. K., Bilal, A., Iftikhar, A., Awais, M., Asif, I., Shaheen, F., & Zahoor, G. (2024). Examining the Association Between Pesticide Exposures and Chronic Diseases in Agricultural Workers. Remittances Review, 9(2), 2153-2176.
11. Huo, D., Ikpatt, F., Khramtsov, A., Dangou, J. M., Nanda, R., Dignam, J., ... & Olopade, O. I. (2012). Population differences in breast cancer: survey in indigenous African women reveals over-representation of HER2-positive breast cancer treatment. Journal of Clinical Oncology, 30(7), 524-530.
12. Noor, A., Bilal, A., & Ali, U. (2024). Towards Personalized Cancer Care: A Report of CRISPR-Cas9 Applications in Targeted Therapies and Precision Medicine. Journal of Health and Rehabilitation Research, 4(2), 1375-1380Jespersen, C. H., Vestergaard, K. R., Schou, M., Teisner, A. S., & Christiansen, M. (2019). PAPP-A inhibitors. Current Pharmaceutical Design, 25(4), 411-418.
13. Jia, J. et al. (2018). Computation-aided discovery of novel sesquiterpenoids with favorable pharmacokinetic profiles from Chinese medicinal plants. Scientific Reports, 8(1), 1-12. https://doi.org/10.1038/s41598-018-27803-4
14. Jiang, S., Jin, L., Qin, Y., & Jia, J. (2018). Virtual screening of natural flavonoid library for PAPP-A inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 1018–1025. https://doi.org/10.1080/14756366.2018.1552522
15. Bilal, A., Ahmad, S., Tanvir, F., Tariq, M., Ramzan, K., Saleem, M., & Saleem, H. G. M. (2022). PREDICTIVE MODELING OF N-ACETYL TRANSFERASE 2 SINGLE NUCLEOTIDE POLYMORPHISMS AND BREAST CANCER RISK USING IN-SILCO APPROACHES. THE JOURNAL OF MICROBIOLOGY AND MOLECULAR GENETICS, 3(2), 105-121.
16. Garcia, C., Silva, C. O., Monteiro, C. M., Nicolai, M., Viana, A., Andrade, J. M., ... & Rijo, P. (2018). Anticancer properties of the abietane diterpene 6, 7-dehydroroyleanone obtained by optimized extraction. Future medicinal chemistry, 10(10), 1177-1189.
17. Kong, F., Chen, Y., Li, L., Liu, X., Lin, L., Wang, Y., ... & Li, L. (2019). Pregnancy-associated plasma protein-A as a potential novel biomarker for HER2-positive breast cancer treatment. Cancer Management and Research, 11, 5125-5133.
18. Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., &

Pietenpol, J. A. (2011). Identification of human HER2-positive breast cancer treatment subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation, 121(7), 2750-2767.

19. Li, J., Wang, K., Chen, X., Meng, H., Song, M., Wang, Y., ... & Zhang, H. (2017). HER2-positive breast cancer treatment therapeutic resistance: where is the Achilles' heel? Cancer Letters, 402, 166-177.
20. Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., ... & Zhang, H. (2017). HER2-positive breast cancer treatment has worse overall survival and cause-specific survival than non-HER2-positive breast cancer treatment
21. Liu, Y. (2021). *In-silico* analysis of absorption, distribution, metabolism, excretion and toxicity properties of lignans. Molecules, 26(3), 644. https://doi.org/10.3390/molecules26030644
22. M Kessler, S., Haybaeck, J., & K Kiemer, A. (2016). Insulin-like growth factor 2-the oncogene and its accomplices. *Current Pharmaceutical Design*, *22*(39), 5948-5961.
23. Marques, R. M., Teixeira, V. H., Correia, M. L., & Ribeiro, A. S. (2016). Pregnancy-associated plasma protein-A is highly expressed in HER2-positive breast cancer treatment and drives a pro-invasive gene expression signature in breast cancer cells. Breast Cancer Research and Treatment, 157(1), 157-166.
24. Moverare-Skrtic, S., Wu, J., Henning, P., Gustafsson, K. L., Sjogren, K., Windahl, S. H., ... & Ohlsson, C. (2017). PAPP- A increases breast cancer cell proliferation by promoting IGFBP-4 proteolysis. Scientific Reports, 7, 42146.
25. Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Telli, M. L. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533.
26. Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., ... & Winer, E. P. (2020). Atezolizumab and nab-paclitaxel in advanced HER2-positive breast cancer treatment. New England Journal of Medicine, 382(21), 2020-2031.
27. Sowers, M. F., Karvonen-Gutierrez, C. A., Palmieri-Smith, R., & Jacobson, J. A. (2004). Associations of biomarkers of inflammation and insulin resistance with the risk of hip fracture: the Women's Health Initiative. Arthritis & Rheumatism, 50(3), 838-846.
28. Bilal, A., Naveed, N., & Haider, M. (2021). A brief note on cancer and its treatment. Occup Med Health Aff, 9(7), 1-3.
29. von Minckwitz, G., Untch, M., Blohmer, J. U., Costa, S. D., Eidtmann, H., Fasching, P. A., ... & Gerber, B. (2012). Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. Journal of Clinical Oncology, 30(15), 1796-1804.
30. Bilal, A., Tanvir, F., Ahmad, S., Shah, S. H. A., Ahmad, H. A., & Kanwal, N. (2024). Pre-clinical study of the bioactive compound Asiaticoside against the proteins inducing human mammary carcinoma using molecular docking and ADME analysis. Remittances Review, 9(2), 3543-3576.
31. Zhang, P. (2019). *In-silico* ADMET evaluation and predictive QSAR modeling of curcuminoids. Molecules, 24(11), 2139.https://doi.org/10.3390/molecules24112139
32. Zhang, X., Zhai, Q., Chen, Y., & Huang, X. (2021). Molecular docking and molecular dynamics simulations reveal the interaction mechanism of flavonoids against pregnancy-associated plasma protein-A. Bioorganic Chemistry, 111, 104795.https://doi.org/10.1016/j.bioorg.2021.104795
33. Ahuja, S., Khan, A. A., & Zaheer, S. (2024). Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2. Pathology-Research and Practice, 155550.